Stay updated on REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial
Sign up to get notified when there's something new on the REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial page.

Latest updates to the REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedRevision: v3.6.6 replaces the prior v3.6.5 on the page, indicating a minor update to the site’s revision stamp. No user-facing content changes are indicated.SummaryDifference0.0%

- Check15 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedA new page revision tag (v3.6.5) was added, updating the page's revision history from v3.6.4. This represents a system-level update and does not modify study content or user-facing information.SummaryDifference0.0%

- Check44 days agoChange DetectedThe revision label was updated from v3.6.3 to v3.6.4, recording a newer internal version of the page.SummaryDifference0.0%

- Check65 days agoChange DetectedThe revision label on the page was updated from v3.6.2 to v3.6.3. This signals a minor page/template update rather than any changes to the study details.SummaryDifference0.0%

- Check73 days agoChange DetectedThe page revision tag changed from v3.6.0 to v3.6.2, representing an internal update to the ClinicalTrials.gov page. Substantive study information remains unchanged.SummaryDifference0.0%

- Check87 days agoChange DetectedRecruitment status updated to No longer looking for participants, indicating the study is not enrolling. New help and navigation sections were added (How to Read a Study Record, Common Questions, How to Join a Study), and the Intervention/Treatment heading was adjusted for consistency.SummaryDifference0.3%

Stay in the know with updates to REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial page.